Phase II
In its first-quarter financial report, Solid Biosciences updated on its Phase I/II IGNITE DMD clinical trial. The progress was marred by adverse events.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
The primary endpoint was objective response rate (ORR). Secondary objectives included duration of response, disease control rate, clinical benefit rate, progression-free survival and overall survival.
PDC*line is a potent, scalable and versatile professional antigen-presenting T-cell with great potential for treating a range of cancers
Genentech, a Roche company, presented data from its FIREFISH clinical trial of risdiplam in Type 1 spinal muscular atrophy (SMA) at the American Academy of Neurology Annual Meeting.
Despite not hitting endpoints, Cytokinetics noted that the FORTITUDE-ALS trial demonstrated consistency of effect for doses, endpoints and timepoints.
Less than one year after securing a toehold in the United States, Korea-based Enzychem Lifesciences hit a major milestone with its pipeline as it eyes completion of its Phase II CRIOM (Chemoradiation Induced Oral Mucositis) study, which could lead to eventual commercialization of a treatment for the serious cancer treatment by-product.
The annual meeting of the American Society of Gene & Cell Therapy (ASGCT) was held in Washington, DC this week, with literally hundreds of abstracts and presentations. Here’s a look at some of the highlights.
When major depressive disorder (MDD) does not respond to at least two different types of antidepressant treatments in a moderate-to-severe depressive episode, it is reclassified as treatment-resistant depression or TRD. South San Francisco-based VistaGen Therapeutics’ AV-101 failed to meet its primary efficacy endpoints for TRD in a Phase II clinical trial.
Pharma, biotech and life science companies from across the globe share data and progress on pipelines and other company events.
PRESS RELEASES